Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

欧泰乐 - NMPA Drug Approval Details

Approvals/NMPA/Apremilast Tablets

Approved

化学药品

Apremilast Tablets

Amgen Inc.🇨🇳 National Medical Products Administration

Approval Date: Aug 12, 2021
Approval ID: 8BYsNKQysSP
Company: Amgen Inc.
Type: 化学药品

Approval Details

Approval Id: 8BYsNKQysSP
Approval Number: 国药准字HJ20210066
Generic Name: 阿普米司特片
Generic Name En: Apremilast Tablets
Trade Name: 欧泰乐
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 20mg
Reg Date: 2021-08-12
Expired Date: 2026-08-11
Company Name: Amgen Inc.

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Aug 12, 2021

Approval ID

8BYsNKQysSP

Type

化学药品

Back to NMPA Approvals